Menu

Experience

Robert L. Jones

    • Cytokinetics – $450 Million Convertible Senior Notes Offering 


    • Portola Agrees to Sell to Alexion for $1.41 Billion 


    • Cell Design Labs Sells to Gilead 


    • Cell Design Labs: Collaboration Agreement with Kite Pharma and Simultaneous Series of Private Financings 


    • Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan 


    • NewLink Genetics Signs $1 Billion Deal with Genentech for Cancer Drug Research & Development